Theravance Biopharma, Inc.
DE ˙ DB ˙ KYG8807B1068
13,60 € ↑0,30 (2,26%)
2026-06-04
AKTIENPREIS
SecurityDE:0TB / Theravance Biopharma, Inc.
InstitutionState Street Corp
Latest Disclosed Ownership1,297,323 shares
Latest Disclosed Value $ 21,055,552
State Street Corp reports 17.74% increase in ownership of 0TB / Theravance Biopharma, Inc.

On May 15, 2026 - State Street Corp filed a 13F-HR form disclosing ownership of 1,297,323 shares of Theravance Biopharma, Inc. (DE:0TB) valued at $17,124,664 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 13, 2026 disclosing 1,101,892 shares of Theravance Biopharma, Inc.. This represents a change in shares of 17.74% during the quarter. The current value of the position is $17,643,593 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F THERAVANCE BIOPHARMA COM G8807B106 1,297,323 195,431 17.74 21,056 2.13 0.0007
2026-02-13 2025-12-31 13F THERAVANCE BIOPHARMA COM G8807B106 1,101,892 45,987 4.36 20,616 33.73 0.0007
2025-11-14 2025-09-30 13F THERAVANCE BIOPHARMA COM G8807B106 1,055,905 20,257 1.96 15,416 34.96 0.0005
2025-08-14 2025-06-30 13F THERAVANCE BIOPHARMA COM G8807B106 1,035,648 -31,127 -2.92 11,423 19.91 0.0004
2025-05-15 2025-03-31 13F THERAVANCE BIOPHARMA COM G8807B106 1,066,775 -155,695 -12.74 9,526 -17.19 0.0004
2025-02-14 2024-12-31 13F THERAVANCE BIOPHARMA COM G8807B106 1,222,470 30,849 2.59 11,503 19.77 0.0005
2024-11-14 2024-09-30 13F THERAVANCE BIOPHARMA COM G8807B106 1,191,621 -75,754 -5.98 9,604 -10.64 0.0004
2024-08-14 2024-06-30 13F THERAVANCE BIOPHARMA COM G8807B106 1,267,375 -101,406 -7.41 10,747 -12.46 0.0005
2024-05-15 2024-03-31 13F THERAVANCE BIOPHARMA COM G8807B106 1,368,781 -21,533 -1.55 12,278 -21.44 0.0005
2024-02-14 2023-12-31 13F THERAVANCE BIOPHARMA COM G8807B106 1,390,314 -80,873 -5.50 15,627 23.09 0.0008
2023-11-14 2023-09-30 13F THERAVANCE BIOPHARMA COM G8807B106 1,471,187 -6,101 -0.41 12,696 -16.96 0.0007
2023-08-14 2023-06-30 13F THERAVANCE BIOPHARMA COM G8807B106 1,477,288 66,280 4.70 15,290 -0.13 0.0008
2023-05-15 2023-03-31 13F THERAVANCE BIOPHARMA COM G8807B106 1,411,008 -21,911 -1.53 15,309 -4.78 0.0009
2023-05-15 2022-12-31 13F/A-99 THERAVANCE BIOPHARMA COM G8807B106 1,432,919 -51,840 -3.49 16,077 6.79 0.0009
2023-05-15 2022-12-31 13F THERAVANCE BIOPHARMA COM G8807B106 1,432,919 -51,840 16,077 0.0009
2022-11-15 2022-09-30 13F THERAVANCE BIOPHARMA COM G8807B106 1,484,759 -10,287 -0.69 15,055 11.15 0.0010
2022-08-15 2022-06-30 13F THERAVANCE BIOPHARMA COM G8807B106 1,495,046 -46,487 -3.02 13,545 -8.09 0.0008
2022-05-16 2022-03-31 13F THERAVANCE BIOPHARMA COM G8807B106 1,541,533 181,331 13.33 14,737 -1.95 0.0007
2022-02-14 2021-12-31 13F THERAVANCE BIOPHARMA COM G8807B106 1,360,202 -12,045 -0.88 15,030 48.01 0.0007
2021-11-15 2021-09-30 13F THERAVANCE BIOPHARMA COM G8807B106 1,372,247 116,189 9.25 10,155 -44.32 0.0005
2021-08-16 2021-06-30 13F THERAVANCE BIOPHARMA COM G8807B106 1,256,058 103,439 8.97 18,238 -22.47 0.0010
2021-07-09 2021-03-31 13F/A-1 THERAVANCE BIOPHARMA COM G8807B106 1,152,619 103,274 9.84 23,525 26.16 0.0013
2021-05-17 2021-03-31 13F THERAVANCE BIOPHARMA COM G8807B106 993,003 -56,342 20,267 0.0012
2021-02-16 2020-12-31 13F THERAVANCE BIOPHARMA COM G8807B106 1,049,345 -42,339 -3.88 18,647 15.53 0.0011
2020-11-10 2020-09-30 13F THERAVANCE BIOPHARMA COM G8807B106 1,091,684 -14,147 -1.28 16,141 -30.46 0.0011
2020-08-14 2020-06-30 13F THERAVANCE BIOPHARMA COM G8807B106 1,105,831 50,563 4.79 23,211 -4.82 0.0017
2020-06-19 2020-03-31 13F/A-1 THERAVANCE BIOPHARMA COM G8807B106 1,055,268 95,704 9.97 24,387 -1.84 0.0021
2020-05-11 2020-03-31 13F THERAVANCE BIOPHARMA COM G8807B106 1,055,268 95,704 24,387 2,141.6696
2020-02-06 2019-12-31 13F THERAVANCE BIOPHARMA COM G8807B106 959,564 11,948 1.26 24,843 34.58 0.0017
2019-11-14 2019-09-30 13F THERAVANCE BIOPHARMA COM G8807B106 947,616 9,112 0.97 18,460 20.45 0.0014
2019-08-14 2019-06-30 13F THERAVANCE BIOPHARMA COM G8807B106 938,504 34,750 3.85 15,326 -25.20 0.0011
2019-05-15 2019-03-31 13F THERAVANCE BIOPHARMA COM G8807B106 903,754 22,108 2.51 20,488 -9.19 0.0016
2019-02-12 2018-12-31 13F THERAVANCE BIOPHARMA COM G8807B106 881,646 -2,152 -0.24 22,561 -21.86 0.0021
2018-11-09 2018-09-30 13F THERAVANCE BIOPHARMA Common equity shares G8807B106 883,798 6,405 0.73 28,871 45.07 0.0022
2018-08-14 2018-06-30 13F THERAVANCE BIOPHARMA Common equity shares G8807B106 877,393 15,942 1.85 19,901 -4.74 0.0017
2018-05-15 2018-03-31 13F THERAVANCE BIOPHARMA Common equity shares G8807B106 861,451 -21,645 -2.45 20,891 -15.18 0.0018
2018-02-14 2017-12-31 13F THERAVANCE BIOPHARMA Common equity shares G8807B106 883,096 -30,740 -3.36 24,631 -21.28 0.0020
2017-11-14 2017-09-30 13F THERAVANCE BIOPHARMA Common equity shares G8807B106 913,836 24,154 2.71 31,289 -11.72 0.0027
2017-08-14 2017-06-30 13F THERAVANCE BIOPHARMA Common equity shares G8807B106 889,682 19,428 2.23 35,443 10.61 0.0031
2017-05-15 2017-03-31 13F THERAVANCE BIOPHARMA Common equity shares G8807B106 870,254 19,230 2.26 32,042 18.08 0.0029
2017-02-09 2016-12-31 13F THERAVANCE BIOPHARMA Common equity shares G8807B106 851,024 131,646 18.30 27,136 4.09 0.0026
2017-01-13 2016-09-30 13F/A-1 THERAVANCE BIOPHARMA Common equity shares G8807B106 719,378 9,807 1.38 26,070 61.94 0.0026
2016-11-14 2016-09-30 13F THERAVANCE BIOPHARMA Common equity shares G8807B106 719,378 26,070
2016-08-12 2016-06-30 13F THERAVANCE BIOPHARMA Common equity shares G8807B106 709,571 165,364 30.39 16,099 57.25 0.0017
2016-05-20 2016-03-31 13F/A-1 THERAVANCE BIOPHARMA Common equity shares G8807B106 544,207 15,574 2.95 10,238 18.22 0.0011
2016-05-12 2016-03-31 13F THERAVANCE BIOPHARMA Common equity shares G8807B106 544,207 10,238
2016-02-16 2015-12-31 13F THERAVANCE BIOPHARMA Common equity shares G8807B106 528,633 -254,231 -32.47 8,660 0.62 0.0009
2015-11-16 2015-09-30 13F THERAVANCE BIOPHARMA Common equity shares G8807B106 782,864 -80,414 -9.31 8,607 -23.40 0.0010
2015-08-13 2015-06-30 13F THERAVANCE BIOPHARMA Common equity shares G8807B106 863,278 -141,631 -14.09 11,236 -35.55 0.0012
2015-05-15 2015-03-31 13F THERAVANCE BIOPHARMA Common equity shares G8807B106 1,004,909 44,749 4.66 17,433 21.72 0.0018
2015-02-11 2014-12-31 13F THERAVANCE BIOPHARMA Common equity shares G8807B106 960,160 -151,877 -13.66 14,322 -44.14 0.0014
2014-11-12 2014-09-30 13F/A-1 THERAVANCE BIOPHARMA Common equity shares G8807B106 1,112,037 517,179 86.94 25,637 35.14 0.0028
2014-11-10 2014-09-30 13F THERAVANCE BIOPHARMA Common equity shares G8807B106 1,112,037 25,637
2014-08-12 2014-06-30 13F THERAVANCE BIOPHARMA Common equity shares G8807B106 594,858 594,858 18,970 0.0020
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.